CME Group (NASDAQ:CME – Get Free Report) had its target price lifted by investment analysts at Barclays from $312.00 to $344.00 in a report issued on Wednesday,MarketScreener reports. The brokerage presently has an “equal weight” rating on the financial services provider’s stock. Barclays‘s target price would suggest a potential upside of 13.90% from the stock’s current price.
A number of other equities analysts have also commented on CME. Deutsche Bank Aktiengesellschaft increased their price target on CME Group from $312.00 to $316.00 and gave the company a “buy” rating in a research note on Thursday, February 5th. UBS Group reissued a “neutral” rating and set a $310.00 price target on shares of CME Group in a research note on Friday, February 6th. Bank of America increased their price target on CME Group from $201.00 to $209.00 in a research note on Wednesday, December 10th. Argus reissued a “hold” rating on shares of CME Group in a research note on Wednesday, March 4th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of CME Group from $262.00 to $266.00 and gave the stock an “underweight” rating in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $307.59.
Check Out Our Latest Analysis on CME
CME Group Stock Performance
CME Group (NASDAQ:CME – Get Free Report) last posted its earnings results on Wednesday, February 4th. The financial services provider reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.75 by $0.02. CME Group had a net margin of 62.45% and a return on equity of 14.65%. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same period last year, the company posted $2.52 earnings per share. CME Group’s quarterly revenue was up 8.1% on a year-over-year basis. As a group, sell-side analysts forecast that CME Group will post 10.49 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Bryan T. Durkin sold 4,200 shares of CME Group stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $309.65, for a total transaction of $1,300,530.00. Following the completion of the transaction, the director directly owned 43,007 shares of the company’s stock, valued at approximately $13,317,117.55. The trade was a 8.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Martin J. Gepsman sold 300 shares of CME Group stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $305.90, for a total transaction of $91,770.00. Following the transaction, the director directly owned 24,999 shares of the company’s stock, valued at approximately $7,647,194.10. This represents a 1.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 8,539 shares of company stock valued at $2,713,821 in the last quarter. 0.30% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On CME Group
A number of large investors have recently made changes to their positions in CME. Norges Bank purchased a new position in shares of CME Group during the 4th quarter worth about $1,523,241,000. Sanders Capital LLC purchased a new stake in CME Group in the 3rd quarter valued at about $1,006,932,000. Strive Asset Management LLC purchased a new stake in CME Group in the 3rd quarter valued at about $636,487,000. Victory Capital Management Inc. boosted its position in CME Group by 746.4% in the 4th quarter. Victory Capital Management Inc. now owns 2,049,649 shares of the financial services provider’s stock valued at $559,720,000 after buying an additional 1,807,491 shares during the period. Finally, Life Cycle Investment Partners Ltd purchased a new stake in CME Group in the 4th quarter valued at about $217,656,000. 87.75% of the stock is owned by hedge funds and other institutional investors.
Key Headlines Impacting CME Group
Here are the key news stories impacting CME Group this week:
- Positive Sentiment: CME reported a record international average daily volume (ADV) of 11.4 million contracts in Q1 2026, up 30% year-over-year, with all major asset classes and regions hitting new highs — a direct driver of higher fee and clearing revenue. CME Group International Average Daily Volume Reaches Record 11.4 Million Contracts in Q1 2026
- Positive Sentiment: CME will expand its regulated crypto suite by launching Avalanche (AVAX) and Sui (SUI) futures on May 4 (pending regulatory approval), adding both standard and micro contract sizes — this widens product breadth for institutional crypto flow and supports future 24/7 crypto derivatives growth. CME Group to Continue Expansion of Regulated Crypto Suite with Launch of Avalanche and Sui Futures
- Positive Sentiment: Raymond James raised its price target on CME to $320 and maintained an “outperform” rating — a vote of confidence that supports upside expectations for the stock as volumes and new product monetization ramp. Raymond James adjusts price target on CME Group to $320
- Positive Sentiment: Crypto markets reacted to the CME futures news (AVAX and SUI surged), which can increase trading activity and notional value traded on CME’s crypto contracts — a short-term volume tailwind. Sui and Avalanche surge as CME futures launch boosts crypto rally
- Neutral Sentiment: Major financial and media outlets are highlighting the ADV milestone and product launches (additional coverage reinforces visibility but duplicates the core news drivers). CME Group Q1 ADV hits new high of 11.4M
- Negative Sentiment: Keefe, Bruyette & Woods reaffirmed a “market perform” rating with a $305 price target — slightly below the current level — reflecting some analyst caution about near-term multiple expansion or sustainability of elevated volumes. Keefe, Bruyette & Woods reaffirms market perform on CME
About CME Group
CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.
The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.
Further Reading
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.
